Amivantamab Boosts Response in Advanced Head and Neck Cancer
Publication Title: Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study.
Summary
- Question
- This study examined the effectiveness of amivantamab, a targeted therapy, for treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who had previously undergone immune checkpoint inhibitor (ICI) therapy and platinum-based chemotherapy. The researchers aimed to evaluate its ability to shrink tumors, its safety profile, and how long patients benefited from the treatment.
- Why it Matters
- Recurrent or metastatic HNSCC is a difficult-to-treat cancer with limited options after standard therapies, such as ICI and chemotherapy, have failed. Current treatments, including paclitaxel and cetuximab, show modest tumor response rates of only 21% to 24%. Amivantamab, a bispecific antibody targeting EGFR (a protein involved in cell growth) and MET (a protein linked to cancer spread), offers a potentially more effective alternative. Understanding its efficacy and safety could provide hope for patients with advanced disease and guide future treatment strategies.
- Methods
- The study, called OrigAMI-4, was a phase 1b/2 clinical trial involving 102 patients with recurrent or metastatic HNSCC who had previously been treated with ICI and platinum-based chemotherapy. Participants received subcutaneous injections of amivantamab every three weeks, and their responses were assessed using RECIST v1.1 criteria, a standard method for measuring tumor shrinkage in clinical trials. The researchers tracked tumor response rates, survival outcomes, and treatment-related side effects.
- Key Findings
- Amivantamab showed a tumor response rate of 42% based on independent central review, with 15% of patients achieving complete tumor shrinkage. Responses lasted at least six months in 56% of cases, and median progression-free survival (the time before the cancer worsened) was 6.8 months. Median overall survival (the time patients lived after starting treatment) was 12.5 months. The treatment was well-tolerated, with side effects consistent with prior studies of amivantamab and a low discontinuation rate of 8%. These outcomes suggest stronger antitumor activity compared to existing therapies for this patient population.
- Implications
- The findings highlight amivantamab as a promising treatment option for patients with recurrent or metastatic HNSCC who have exhausted standard therapies. Its higher response rates and prolonged survival compared to paclitaxel and cetuximab may improve outcomes for this challenging cancer. These results also underscore the potential of therapies targeting EGFR and MET to address the unmet needs in advanced HNSCC treatment.
- Next Steps
- The authors suggest further research to confirm amivantamab’s benefits in larger, randomized clinical trials. Additional studies may also explore its effectiveness in combination with other treatments or in different stages of HNSCC to maximize its therapeutic potential.
- Funding Information
- The publication does not explicitly mention sources of funding or specific grants that supported this research. Yale University also provided funding and support for this research.
Full Citation
Burtness B, Rosenberg AJ, Calderon B, Lim SM, Yang MH, Li SH, Kadowaki S, Swiecicki PL, Geiger JL, Ince W, Hahn D, Guo Y, Adkins D, Metcalf R, Ahn MJ, Sukari A, Braña I, Keam B, Tanaka H, Sheth S, Oliva M, Lyu X, Curtin JC, Toyoizumi K, Xie J, Wade M, Diorio B, Kapoor A, Yilmaz E, Baig M, Kim P, Verheijen RB, Shah S, Harrington KJ. Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study. J Clin Oncol 2026, 101200JCO2601042. PMID: 42218660, DOI: 10.1200/JCO-26-01042.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Barbara Burtness, MD
First AuthorAnthony N. Brady Professor of Medicine (Medical Oncology)
Media
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study